Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the ...
Pharmabiz

Merck’s Idvynso, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir gets US FDA approval for the treatment of HIV-1 infection

Merck’s Idvynso, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir gets US FDA approval for the treatment of HIV-1 infection: Rahway, New Jersey ...